Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$291.80
-1.6%
$246.06
$144.26
$303.30
$14.15B1.38972,035 shs659,833 shs
Icon Plc stock logo
ICLR
Icon
$170.02
+0.2%
$167.20
$66.57
$203.91
$13.00B1.21583,511 shs314,629 shs
7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
-1.73%-1.16%+23.85%+61.17%+79.40%
Icon Plc stock logo
ICLR
Icon
+0.18%-1.28%-4.23%+24.95%-2.29%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$291.80
-1.6%
$246.06
$144.26
$303.30
$14.15B1.38972,035 shs659,833 shs
Icon Plc stock logo
ICLR
Icon
$170.02
+0.2%
$167.20
$66.57
$203.91
$13.00B1.21583,511 shs314,629 shs
7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
-1.73%-1.16%+23.85%+61.17%+79.40%
Icon Plc stock logo
ICLR
Icon
+0.18%-1.28%-4.23%+24.95%-2.29%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
2.69
Moderate Buy$255.65-12.39% Downside
Icon Plc stock logo
ICLR
Icon
2.41
Hold$170.400.22% Upside

Current Analyst Ratings Breakdown

Latest ICLR and CRL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/26/2026
Icon Plc stock logo
ICLR
Icon
Reiterated RatingSell (D)
8/10/2026
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Boost Price TargetBuy$235.00 ➝ $300.00
8/10/2026
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Set Price Target$300.00
8/10/2026
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Set Price Target$264.00
8/7/2026
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Boost Price TargetOverweight$260.00 ➝ $300.00
8/6/2026
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Set Price Target$291.00
8/6/2026
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Boost Price TargetOutperform$215.00 ➝ $282.00
8/6/2026
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
UpgradeNeutralOverweight$180.00 ➝ $310.00
8/5/2026
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Reiterated RatingOverweight$300.00
8/5/2026
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Reiterated RatingOutperform
7/31/2026
Icon Plc stock logo
ICLR
Icon
Set Price Target$194.00
(Data available from 8/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$4.02B3.47$21.61 per share13.50$59.62 per share4.89
Icon Plc stock logo
ICLR
Icon
$8.25B1.58$16.88 per share10.07$122.48 per share1.39
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
-$144.34M-$4.85N/A23.183.08-5.96%15.75%6.51%11/4/2026 (Estimated)
Icon Plc stock logo
ICLR
Icon
$229.34M$4.2639.9115.717.033.99%8.02%4.56%10/28/2026 (Estimated)

Latest ICLR and CRL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2026Q2 2026
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$2.77$3.02+$0.25-$0.03$980.53 million$1.00 billion
7/30/2026Q1 2026
Icon Plc stock logo
ICLR
Icon
$2.55$2.56+$0.01$0.94$2.00 billion$2.06 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
N/AN/AN/AN/AN/A
Icon Plc stock logo
ICLR
Icon
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
0.92
1.35
1.04
Icon Plc stock logo
ICLR
Icon
0.23
0.95
0.95

Institutional Ownership

CompanyInstitutional Ownership
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
98.91%
Icon Plc stock logo
ICLR
Icon
95.61%

Insider Ownership

CompanyInsider Ownership
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
1.30%
Icon Plc stock logo
ICLR
Icon
44.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
19,70047.74 million47.12 millionOptionable
Icon Plc stock logo
ICLR
Icon
40,10076.57 million42.88 millionOptionable

Recent News About These Companies

Icon (NASDAQ:ICLR) Director Sells 841 Shares
Icon (NASDAQ:ICLR) CFO Sells 2,267 Shares
Icon (NASDAQ:ICLR) CEO Sells $62,674.74 in Stock

New MarketBeat Followers Over Time

Media Sentiment Over Time

Charles River Laboratories International stock logo

Charles River Laboratories International NYSE:CRL

$291.80 -4.61 (-1.56%)
As of 08/28/2026 03:58 PM Eastern

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Icon stock logo

Icon NASDAQ:ICLR

$170.02 +0.30 (+0.18%)
As of 08/28/2026 04:00 PM Eastern

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, it offers adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.